Headlines
Bayer seeks investor approval for 35% cash call to gird for litigation
Published by Global Banking & Finance Review®
Posted on March 7, 2025
1 min readLast updated: January 25, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on March 7, 2025
1 min readLast updated: January 25, 2026
Bayer plans to raise equity capital worth 35% of its shares to prepare for potential US litigation settlements, impacting its share price.
FRANKFURT (Reuters) -Bayer said on Friday it would seek shareholder approval to raise fresh equity capital worth close to 35% of its currently outstanding shares over the next three years to be ready for any U.S. litigation settlement.
The so-called "Authorized Capital 2025" shall only be used "if it is absolutely necessary", it said in a statement on its website.
"It cannot be ruled out, however, that the Company will need to increase the capital stock at short notice in the future, for example in view of potential future settlements with plaintiffs in the United States or in connection with measures to substantially contain litigations in the United States," it added.
Bayer shares were down 7.6% at 1115 GMT.
(Reporting by Ludwig Burger, Editing by Friederike Heine)
Bayer's plan to raise equity capital to prepare for potential US litigation settlements.
To be ready for any potential US litigation settlements and manage related risks.
Bayer shares fell by 7.6% following the announcement.
Explore more articles in the Headlines category
